7 results on '"Meifeng Yin"'
Search Results
2. Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure
- Author
-
Junxia Hu, Xin Wang, Fei Chen, Mengjie Ding, Meng Dong, Wanqiu Yang, Meifeng Yin, Jingjing Wu, Lei Zhang, Xiaorui Fu, Zhenchang Sun, Ling Li, Xinhua Wang, Xin Li, Shuangshuang Guo, Dianbao Zhang, Xiaohui Lu, Qing Leng, Mingzhi Zhang, Linan Zhu, Xudong Zhang, and Qingjiang Chen
- Subjects
decitabine ,chemotherapy ,diffuse large B cell lymphoma ,modified DHAP regimen ,safety ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
ObjectiveThe prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R-DLBCL) after second-line treatment failure is extremely poor. This study prospectively observed the efficacy and safety of decitabine with a modified cisplatin, cytarabine, and dexamethasone (DHAP) regimen in R/R-DLBCL patients who failed second-line treatment.MethodsTwenty-one R/R-DLBCL patients were enrolled and treated with decitabine and a modified DHAP regimen. The primary endpoints were overall response rate (ORR) and safety. The secondary endpoints were progression-free survival (PFS) and overall survival (OS).ResultsORR reached 50% (complete response rate, 35%), five patients (25%) had stable disease (SD) with disease control rate (DCR) of 75%. Subgroup analysis revealed patients over fifty years old had a higher complete response rate compared to younger patients (P = 0.005), and relapsed patients had a better complete response rate than refractory patients (P = 0.031). Median PFS was 7 months (95% confidence interval, 5.1-8.9 months). Median OS was not achieved. One-year OS was 59.0% (95% CI, 35.5%-82.5%), and two-year OS was 51.6% (95% confidence interval, 26.9%-76.3%). The main adverse events (AEs) were grade 3/4 hematologic toxicities such as neutropenia (90%), anemia (50%), and thrombocytopenia (70%). Other main non-hematologic AEs were grade 1/2 nausea/vomiting (40%) and infection (50%). No renal toxicity or treatment-related death occurred.ConclusionDecitabine with a modified DHAP regimen can improve the treatment response and prognosis of R/R-DLBCL patients with good tolerance to AEs, suggesting this regimen has potential as a possible new treatment option for R/R-DLBCL patients after second-line treatment failure.Clinical Trial RegistrationClinicalTrials.gov, identifier: NCT03579082.
- Published
- 2021
- Full Text
- View/download PDF
3. TIPE2 suppresses progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/β-catenin pathway
- Author
-
Linan Zhu, Xudong Zhang, Xiaorui Fu, Zhaoming Li, Zhenchang Sun, Jingjing Wu, Xinhua Wang, Feng Wang, Xiangke Li, Songtao Niu, Mengjie Ding, Zhenzhen Yang, Wanqiu Yang, Meifeng Yin, Lei Zhang, and Mingzhi Zhang
- Subjects
Esophageal carcinoma ,TIPE2 ,Proliferation ,Tumorigenesis ,Wnt/β-catenin pathway ,Medicine - Abstract
Abstract Background Esophageal carcinoma is the eighth prevalent malignancy and ranks the sixth in carcinoma-related death worldwide. Tumor necrosis factor-α-induced protein-8 like-2 (TIPE2) has been identified as a tumor suppressor in multiple carcinomas. However, its roles and molecular mechanisms underlying esophageal carcinoma progression are still undefined till now. Methods RT-qPCR assay was employed to detect the expression of TIPE2 mRNA. TIPE2 protein expression was measured by using western blot assay. Ad-V and Ad-TIPE2 adenoviruses were constructed to overexpress TIPE2. The effects of TIPE2 overexpression on cell proliferation, invasion and apoptosis were assessed by MTT and Edu incorporation assays, transwell invasion assay and flow cytometry analysis, respectively. The effect of TIPE2 overexpression on xenograft tumor growth was determined by measuring tumor volume and weight, together with immunohistochemistry assay. The effect of TIPE2 overexpression on the Wnt/β-catenin signaling pathway was evaluated by detecting the protein levels of β-catenin, c-Myc and cyclinD1 in EC9076 cells and xenograft tumors of esophageal carcinoma. Results TIPE2 expression was downregulated in esophageal carcinoma tissues and cells. Adenovirus-mediated TIPE2 overexpression suppressed cell proliferation and invasion, and induced apoptosis in esophageal carcinoma cells. Enforced expression of TIPE2 inhibited tumor growth in vivo, as evidenced by the reduced tumor volume, tumor weight and proliferating cell nuclear antigen expression. Overexpression of TIPE2 inhibited the Wnt/β-catenin signaling pathway in esophageal carcinoma in vitro and in vivo. Conclusions These results suggest that TIPE2 suppressed progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/β-catenin pathway.
- Published
- 2018
- Full Text
- View/download PDF
4. Predictive value of N-terminal pro-B-type natriuretic peptide (NT-pro BNP) combined with D-dimer for no-reflow phenomenon in patients with acute coronary syndrome after emergency of percutaneous coronary intervention
- Author
-
Baoguo Zhang, Meifeng Yin, Yujing Diao, and Bin Sun
- Subjects
Male ,medicine.medical_specialty ,Acute coronary syndrome ,no-reflow phenomenon ,medicine.drug_class ,medicine.medical_treatment ,Bioengineering ,Logistic regression ,Applied Microbiology and Biotechnology ,Fibrin Fibrinogen Degradation Products ,Internal medicine ,Natriuretic Peptide, Brain ,D-dimer ,medicine ,Natriuretic peptide ,Humans ,In patient ,cardiovascular diseases ,business.industry ,percutaneous coronary intervention ,Percutaneous coronary intervention ,General Medicine ,Middle Aged ,medicine.disease ,Peptide Fragments ,NT-proBNP ,Conventional PCI ,No reflow phenomenon ,cardiovascular system ,Cardiology ,Female ,business ,TP248.13-248.65 ,hormones, hormone substitutes, and hormone antagonists ,Research Article ,Research Paper ,Biotechnology - Abstract
Acute coronary syndrome (ACS) is a critical illness in cardiovascular disease. The purpose of this study was to investigate the value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and D-dimer in predicting the occurrence of no reflow in emergency percutaneous coronary intervention (PCI) in patients with ACS. One hundred and sixty-eight ACS patients were recruited, including 88 patients with normal reflow and 80 patients with no reflow after emergency PCI. The levels of serum NT-proBNP and D-dimer in the patients were detected before PCI, immediately after PCI, 2 hours, and 6 months after PCI. The ROC curve was used to evaluate the predictive value of NT-proBNP and D-dimer in no-reflow phenomenon. Logistic regression model was used to analyze the independent influencing factors of no reflow phenomenon. Logistic regression analysis confirmed that NT-proBNP and D-dimer were independent predictors of the occurrence of no reflow in the total population. The ROC curve showed that the AUC value was 0.909 when NT-proBNP combined with D-dimer. The detection of NT-proBNP combined with D-dimer was helpful to predict the occurrence of no-reflow phenomenon after emergency PCI in ACS patients.
- Published
- 2021
- Full Text
- View/download PDF
5. microRNA-605 directly targets SOX9 to alleviate the aggressive phenotypes of glioblastoma multiforme cell lines by deactivating the PI3K/Akt pathway
- Author
-
Jing Wang, Jianwu Jia, Meifeng Yin, and Yongdong Liu
- Subjects
0301 basic medicine ,malignant phenotypes ,SRY-Box 9 ,Biology ,OncoTargets and Therapy ,law.invention ,03 medical and health sciences ,glioblastoma multiforme ,0302 clinical medicine ,Downregulation and upregulation ,In vivo ,law ,microRNA ,Gene silencing ,Pharmacology (medical) ,PI3K/AKT/mTOR pathway ,Original Research ,Phenotype ,Retraction ,microRNA-605 ,030104 developmental biology ,Oncology ,Cell culture ,030220 oncology & carcinogenesis ,Cancer research ,Suppressor - Abstract
Jianwu Jia,1,*Jing Wang,1,*Meifeng Yin,1 Yongdong Liu21Department of Neurosurgery, Yidu Central Hospital of Weifang, Weifang, Shandong 262500, People’s Republic of China; 2Department of Pediatrics, Weifang People’s Hospital, Weifang, Shandong 261041, People’s Republic of China*These authors contributed equally to this workBackground: Aberrant microRNA (miRNA) expression has been widely reported to play a crucial role in the progression and development of glioblastoma (GBM). miR-605 has been identified as a tumor-suppressing miRNA in several types of human cancers. Nevertheless, the expression profile and detailed roles of miR-605 in GBM remain unclear and need to be further elucidated.Materials and methods: RT-qPCR analysis was utilized for the determination of miR-605 expression in GBM tissues and cell lines. In addition, CCK-8 assay, transwell migration and invasion assays, as well as sub-cutaneous xenograft mouse models were utilized to evaluate the effects of miR-605 upregulation in GBM cells. Notably, the potential mechanisms underlying the activity of miR-605 in the malignant phenotypes of GBM were explored.Results: We observed that expression of miR-605 was reduced in GBM tissues and cell lines. Decreased miR-605 expression exhibited significant correlation with KPS score. The overall survival rate in GBM patients with low miR-605 expression was lower than that of patients with high miR-605 expression. Increased miR-605 expression suppressed the proliferation, migration, and invasion of U251 and T98 cells. In addition, miR-605 upregulation impaired tumor growth in vivo. Furthermore, SRY-Box 9 (SOX9) was identified as a direct target gene of miR-605 in U251 and T98 cells. SOX9 expression was shown to exhibit an inverse correlation with miR-605 expression in GBM tissues. Moreover, silencing of SOX9 expression mimicked the tumor-suppressing roles of miR-605 in U251 and T98 cells, while SOX9 restoration rescued the suppressive effects of miR-605 overexpression in the same. Notably, miR-605 suppressed the PI3K/Akt pathway in GBM in vitro and in vivo.Conclusion: These results demonstrated that miR-605 acts as a tumor suppressor in the development of GBM by directly targeting SOX9 and inhibiting the activation of the PI3K/Akt pathway, suggesting its potential role as a therapeutic target for GBM.Keywords: glioblastoma multiforme, microRNA-605, malignant phenotypes, SRY-Box 9
- Published
- 2019
6. c-Myc mediated upregulation of long noncoding RNA SNHG12 regulates proliferation and drug sensitivity in natural killer/T-cell lymphoma
- Author
-
Wanqiu Yang, Zhenzhen Yang, Xinhua Wang, Xiangke Li, Feng Wang, Zhenchang Sun, Mingzhi Zhang, Mengjie Ding, Zhaoming Li, Jingjing Wu, Lei Zhang, Linan Zhu, Meifeng Yin, Xiaorui Fu, Songtao Niu, and Xudong Zhang
- Subjects
0301 basic medicine ,Antineoplastic Agents ,Biology ,Biochemistry ,Cell Line ,Proto-Oncogene Proteins c-myc ,03 medical and health sciences ,0302 clinical medicine ,Downregulation and upregulation ,medicine ,Humans ,Small nucleolar RNA ,Molecular Biology ,Gene ,Cell Proliferation ,Cisplatin ,Cell Biology ,Natural killer T cell ,medicine.disease ,Long non-coding RNA ,Lymphoma ,Gene Expression Regulation, Neoplastic ,Lymphoma, Extranodal NK-T-Cell ,030104 developmental biology ,Cell culture ,Drug Resistance, Neoplasm ,030220 oncology & carcinogenesis ,Cancer research ,RNA, Long Noncoding ,medicine.drug - Abstract
Nasal-type natural killer/T-cell lymphoma (NKTCL) is an aggressive malignancy with poor outcomes. The treatment of NKTCL requires intensive chemotherapy. Long noncoding RNAs (lncRNAs) have been implicated in many cancers, including NKTCL. The elucidation of the multidrug resistance (MDR) may greatly contribute to explore novel therapeutic strategies. Herein, we explored the roles and potential regulatory mechanism of lncRNAs small nucleolar RNA host gene 12 (SNHG12) in MDR of NKTCL. We found that SNHG12 was upregulated in NKTCL tissue sections, and its high expression was positively correlated with clinical grade of malignancy of NKTCL. c-Myc and SNHG12 expression was upregulated in NKTCL cell lines. c-Myc- and SNHG12 overexpression promoted proliferation and inhibited sensitivity to cisplatin (CDDP) in NK/T-cell lymphoma cell line YTS cells, and c-Myc and SNHG12-downregulation inhibited proliferation and enhanced sensitivity to CDDP in SNK-6 cells. Moreover, c-Myc- and SNHG12 overexpression increased Ki67 and P-gp expression in YTS cells, whereas c-Myc and SNHG12-downregulation reduced the Ki67 and P-gp expression in SNK-6 cells. Correlational analyses revealed that c-Myc expression was positively correlated with SNHG12 expression in NKTCL tissues. Mechanism research showed that SNHG12 was a direct transcriptional target of c-Myc and c-Myc promoted SNHG12 expression in NKTCL cell lines. Further research showed that SNHG12 overexpression reversed the effects of c-Myc downregulation on proliferation and sensitivity to CDDP in NKTCL cell lines. Taken together, our findings first report that c-Myc mediated upregulation of SNHG12 promotes proliferation and inhibits drug sensitivity in NKTCL, which provides new insights into the therapeutic target for NKTCL.
- Published
- 2018
7. TIPE2 suppresses progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/β-catenin pathway
- Author
-
Mengjie Ding, Zhaoming Li, Xiangke Li, Feng Wang, Meifeng Yin, Jingjing Wu, Zhenchang Sun, Xinhua Wang, Wanqiu Yang, Songtao Niu, Zhenzhen Yang, Xudong Zhang, Linan Zhu, Lei Zhang, Xiaorui Fu, and Mingzhi Zhang
- Subjects
0301 basic medicine ,Male ,Esophageal Neoplasms ,Carcinogenesis ,Proliferation ,lcsh:Medicine ,Down-Regulation ,Mice, Nude ,Apoptosis ,medicine.disease_cause ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,0302 clinical medicine ,Gentamicin protection assay ,Cell Line, Tumor ,Carcinoma ,medicine ,Wnt/β-catenin pathway ,Animals ,Humans ,Neoplasm Invasiveness ,Wnt Signaling Pathway ,Aged ,Cell Proliferation ,Mice, Inbred BALB C ,Chemistry ,Cell growth ,Research ,lcsh:R ,Wnt signaling pathway ,Intracellular Signaling Peptides and Proteins ,General Medicine ,Middle Aged ,medicine.disease ,Xenograft Model Antitumor Assays ,TIPE2 ,Gene Expression Regulation, Neoplastic ,030104 developmental biology ,Esophageal carcinoma ,030220 oncology & carcinogenesis ,Catenin ,Tumorigenesis ,Cancer research ,Disease Progression ,Tumor necrosis factor alpha ,Female - Abstract
Background Esophageal carcinoma is the eighth prevalent malignancy and ranks the sixth in carcinoma-related death worldwide. Tumor necrosis factor-α-induced protein-8 like-2 (TIPE2) has been identified as a tumor suppressor in multiple carcinomas. However, its roles and molecular mechanisms underlying esophageal carcinoma progression are still undefined till now. Methods RT-qPCR assay was employed to detect the expression of TIPE2 mRNA. TIPE2 protein expression was measured by using western blot assay. Ad-V and Ad-TIPE2 adenoviruses were constructed to overexpress TIPE2. The effects of TIPE2 overexpression on cell proliferation, invasion and apoptosis were assessed by MTT and Edu incorporation assays, transwell invasion assay and flow cytometry analysis, respectively. The effect of TIPE2 overexpression on xenograft tumor growth was determined by measuring tumor volume and weight, together with immunohistochemistry assay. The effect of TIPE2 overexpression on the Wnt/β-catenin signaling pathway was evaluated by detecting the protein levels of β-catenin, c-Myc and cyclinD1 in EC9076 cells and xenograft tumors of esophageal carcinoma. Results TIPE2 expression was downregulated in esophageal carcinoma tissues and cells. Adenovirus-mediated TIPE2 overexpression suppressed cell proliferation and invasion, and induced apoptosis in esophageal carcinoma cells. Enforced expression of TIPE2 inhibited tumor growth in vivo, as evidenced by the reduced tumor volume, tumor weight and proliferating cell nuclear antigen expression. Overexpression of TIPE2 inhibited the Wnt/β-catenin signaling pathway in esophageal carcinoma in vitro and in vivo. Conclusions These results suggest that TIPE2 suppressed progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/β-catenin pathway.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.